Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold

by · The Cerbat Gem

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Sunday.

AVTX has been the subject of a number of other research reports. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Guggenheim set a $48.00 price objective on shares of Avalo Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Finally, Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research note on Wednesday, May 6th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Read Our Latest Research Report on AVTX

Avalo Therapeutics Stock Up 1.8%

Shares of Avalo Therapeutics stock opened at $19.95 on Friday. Avalo Therapeutics has a 12-month low of $8.41 and a 12-month high of $24.27. The stock has a market cap of $1.07 billion, a P/E ratio of -4.57 and a beta of 0.80. The business’s 50 day moving average is $17.96 and its 200-day moving average is $16.46.

Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, sell-side analysts expect that Avalo Therapeutics will post -2.59 EPS for the current year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at $931,968. This represents a 2.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics in the third quarter valued at approximately $143,000. Boothbay Fund Management LLC acquired a new stake in Avalo Therapeutics during the 2nd quarter worth approximately $56,000. AlphaCentric Advisors LLC acquired a new stake in Avalo Therapeutics during the 1st quarter worth approximately $174,000. Jump Financial LLC bought a new stake in Avalo Therapeutics in the 4th quarter valued at $238,000. Finally, Persistent Asset Partners Ltd bought a new stake in Avalo Therapeutics in the 4th quarter valued at $274,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

(Get Free Report)

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

Read More